Monitoring Platelet Function During Continuous Hemodialysis

Completed

• Conditions: Platelet Function

• Registration Number: NCT01837758
• Lead Sponsor: Goethe University

Brief Summary

Aim of the study is a description of changes in platelet function during continuous veno-venous hemodialysis or hemofiltration in patients on an intensive care unit using the Multiplate system.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-12
• Study First Submitted: 2013-04-16
• Study First Submitted QC: 2013-04-18
• Study First Posted: 2013-04-23
• Primary Completion: 2013-08
• Study Completion: 2013-08
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-02
• Last Update Posted: 2017-03-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Need for a continuous renal replacement therapy
• Platelet Count >100.000/nl

Exclusion Criteria

• Pregnancy
• Age <18 years
• Renal replacement therapy within the 7 days prior to enrollment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ASPItest	Baseline, 6, 12, 24 and 48 hours	Area under the aggregation curve (AUC) after platelet stimulation with arachidonic acid at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration.

Secondary Outcome Measures

Name	Time	Method
ADPtest	Baseline, 6, 12, 24 and 48 hours	Area under the aggregation curve (AUC) after platelet stimulation with adenosine diphosphate at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration.
CT-INTEM	Baseline, 6, 12, 24 and 48 hours	Clotting time (CT) in the intrinsically activated rotational thrombelastometry (ROTEM) recorded in seconds at baseline and 6, 12, 24 and 48 hours after the start of continuous veno-venous hemofiltration.
MCF-INTEM	Baseline, 6, 12, 24 and 48hours	Maximum clot firmness (MCF) in the intrinsically activated rotational thrombelastometry (ROTEM) recorded in millimeters at baseline and 6, 12, 24 and 48 hours after the start of continuous veno-venous hemofiltration.
TRAPtest	Baseline, 6, 12, 24, 48 hours	Area under the aggregation curve (AUC) after platelet stimulation with thrombin-receptor-activating peptide 6 (TRAP-6) at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration.

Trial Locations

Locations (1)

Johann Wolfgang Goethe-University; 🇩🇪 Frankfurt, Hessen, Germany